We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Lilly's Kisunlaβ’ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire INDIANAPOLIS, Sept. 24, 2024 Japan is the second major market where...
FDA Approves Lilly's EBGLYSSβ’ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis PR Newswire INDIANAPOLIS, Sept. 13, 2024 EBGLYSS provides a...
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment PR Newswire INDIANAPOLIS, Sept. 12, 2024 Company ups manufacturing investment in Limerick by $1 billion; unveils new...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.114 | -0.120762734831 | 922.47 | 939.86 | 902.3 | 3737056 | 916.86947285 | CS |
4 | -30.214 | -3.17517366037 | 951.57 | 972.48 | 893 | 2737082 | 925.32317408 | CS |
12 | 19.556 | 2.16855178532 | 901.8 | 972.53 | 747.55 | 3312299 | 888.80338295 | CS |
26 | 151.086 | 19.6146805666 | 770.27 | 972.53 | 718.3 | 2939786 | 846.16522301 | CS |
52 | 368.826 | 66.7522125495 | 552.53 | 972.53 | 516.57 | 3082854 | 739.30739119 | CS |
156 | 689.306 | 297.050635639 | 232.05 | 972.53 | 220.2 | 2995536 | 477.13053557 | CS |
260 | 806.996 | 705.662819168 | 114.36 | 972.53 | 101.36 | 3260064 | 336.47597465 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions